Sera Prognostics, Inc. $SERA Shares Bought by Sanders Morris Harris LLC

Key Points

• Sanders Morris Harris LLC significantly increased its stake in Sera Prognostics by 179.8%, owning 263,600 shares valued at approximately $730,000 by the end of the last quarter.
• Sera Prognostics has received a consensus rating of "Sell" from analysts, with recent downgrades from Wall Street Zen and Weiss Ratings.
• CEO Zhenya Lindgardt sold 21,158 shares of stock on September 9th, resulting in a 2.54% decrease in their ownership, while insiders collectively sold 50,631 shares in the last quarter.

Sanders Morris Harris LLC raised its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 179.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 263,600 shares of the company's stock after purchasing an additional 169,400 shares during the period. Sanders Morris Harris LLC owned 0.70% of Sera Prognostics worth $730,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Sera Prognostics during the 1st quarter worth about $39,000. Abel Hall LLC acquired a new position in shares of Sera Prognostics during the second quarter valued at approximately $31,000. Wagner Wealth Management LLC purchased a new position in shares of Sera Prognostics in the second quarter valued at approximately $34,000. Nuveen LLC acquired a new stake in shares of Sera Prognostics in the first quarter worth approximately $138,000. Finally, Rhumbline Advisers boosted its stake in shares of Sera Prognostics by 10.7% in the first quarter. Rhumbline Advisers now owns 39,970 shares of the company's stock worth $147,000 after acquiring an additional 3,869 shares during the last quarter. Hedge funds and other institutional investors own 54.64% of the company's stock.

Analysts Set New Price Targets

SERA has been the subject of several recent research reports. Wall Street Zen downgraded Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Sera Prognostics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Sera Prognostics currently has a consensus rating of "Sell".

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of Sera Prognostics stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the sale, the chief executive officer owned 811,136 shares in the company, valued at $2,555,078.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 50,631 shares of company stock valued at $153,604 in the last quarter. 13.50% of the stock is owned by insiders.

Sera Prognostics Stock Performance

NASDAQ SERA opened at $3.37 on Tuesday. The stock's fifty day moving average is $2.99 and its two-hundred day moving average is $2.70. The firm has a market capitalization of $126.96 million, a P/E ratio of -3.96 and a beta of 0.97. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. As a group, sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.